Overview

* Agios Q2 2025 product revenue rises to $12.5 mln, beating analyst expectations

* Co ends Q2 with $1.3 bln in cash, down from $1.5 bln at year-end 2024

* Agios prepares for potential U.S. approval of PYRUKYND for thalassemia in Sept 2025

Outlook

* Agios expects PYRUKYND approval for thalassemia by September 7, 2025

Result Drivers

* PYRUKYND SALES - Generated $12.5 mln in Q2 2025, up from $8.6 mln in Q2 2024, driven by increased patient enrollment

* EUROPEAN EXPANSION - Entered distribution agreement with Avanzanite Bioscience for PYRUKYND sales in European markets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $12.46 $9.48

Product mln mln (8

Revenue Analysts

)

Q2 EPS -$1.93

Q2 Net -$112.02

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Agios Pharmaceuticals Inc ( AGIO ) is $53.50, about 29.8% above its July 30 closing price of $37.54

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)